Affinium closes $15M Series B round for lead anti-staphylococcal agent
This article was originally published in Scrip
Executive Summary
Affinium Pharmaceuticals, a company focused on novel antibacterials targeting the bacterial fatty acid synthesis (FASII) pathway based in Austin, Texas, with Canadian operations in Ontario, has raised $15 million in a Series B round. New investor Ontario Emerging Technologies Fund joined existing investors SV Life Sciences, Genesis Capital, and Forward Ventures.